MedPath

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

Phase 4
Completed
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Registration Number
NCT00807846
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Brief Summary

This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
201
Inclusion Criteria
  • Polyarticular (both rheumatoid factor positive and rheumatoid factor negative),oligoarticular and extended oligoarticular JIA for ≥3 months meeting the International League of Associations for Rheumatology (ILAR) criteria for Juvenile Idiopathic Arthritis (JIA)
  • Subjects with Systemic JIA with active arthritis in at least 1 joint but without active systemic features are eligible
  • ≥2 years of age and <18 years of age prior to the Baseline visit
  • Body weight ≥10 kg at the Baseline visit
  • Candidate for chronic NSAID therapy in the Investigator's judgment
Exclusion Criteria
  • Psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis types of JIA
  • Active systemic features over the prior 12 weeks in children with systemic Juvenile Idiopathic Arthritis (JIA)
  • Subjects with psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis should be excluded
  • Subjects with active Systemic JIA should not be enrolled

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CelecoxibCelecoxib-
NaproxenNaproxen-
Primary Outcome Measures
NameTimeMethod
Change From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit6 Weeks/Final Visit

Value at 6 weeks minus value at baseline.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline to Week 2 in SBP.2 weeks

Value at 2 weeks minus value at baseline.

Change From Baseline in SBP at Week 4.4 weeks

Value at 4 weeks minus value at baseline.

Number of Participants With >= 30% Improvement in the Participant's Global Assessment of Overall Well-being at Week 6/Final Visit.Week 6/Final Visit

Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.

Change From Baseline in Diastolic Blood Pressure (DBP) at Week 2.2 weeks

Value at 2 weeks minus value at baseline.

Change From Baseline in DBP at Week 4.4 weeks

Value at 4 weeks minus value at baseline.

Change From Baseline in DBP at Week 6/Final Visit6 weeks

Value at 6 weeks/Final Visit minus value at baseline.

Number of Participants With >= 30% Improvement in the Parent's Global Assessment of Overall Well-being at Week 6/Final Visit.Week 6/Final Visit

The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.

Change From Baseline in Parent's Assessment of Overall Well-being at Week 6/Final Visit.6 weeks

The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.

Change From Baseline in Participant's Assessment of Overall Well-being at Week 6/Final Visit.6 weeks

Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.

Trial Locations

Locations (39)

University of Nebraska Medical Center Pediatric Research Office

🇺🇸

Omaha, Nebraska, United States

Hospital Roberto del Rio

🇨🇱

Santiago, RM, Chile

Institute of Rheumatology

🇷🇸

Belgrade, Serbia

Children's Clinic of Internal Medicine

🇷🇸

Nis, Serbia

Zaporizhzhya Regional Clinical Pediatric Hospital

🇺🇦

Zaporizhzhya, Ukraine

Clinica San Borja/Centro de Investigacion de Reumatologia

🇵🇪

San Borja, Lima, Peru

SEIHPE "Smolensk State Medical Academy"of the Minzdravsocrazvitiya of Russia

🇷🇺

Smolensk, Russian Federation

Universitaets-Kinderspital

🇨🇭

Ch-8032 Zuerich, Switzerland

Kyiv City Children Clinical Hospital #1

🇺🇦

Kyiv, Ukraine

Hospital Regional de Concepcion Guillermo Grant Benavente

🇨🇱

Concepcion, VIII Region, Chile

Instituto de Atencion Pediatrica

🇨🇷

San Jose, Costa Rica

CHUV - Unit of Immuno-Allergology and Rhumatology

🇨🇭

Ch-1011 Lausanne, Switzerland

Connecticut Children's Medical Center

🇺🇸

Hartford, Connecticut, United States

State Healthcare Institution of Moscow "Izmailovskaya City Children's Hospital"

🇷🇺

Moscow, Russian Federation

Crimean State Medical University, Chair of Pediatrics with a course of Children Infectious Diseases

🇺🇦

Simferopol, Ukraine

Catalina Pointe Clinical Research, Inc.

🇺🇸

Tucson, Arizona, United States

Arkansas Children's Hospital

🇺🇸

Little Rock, Arkansas, United States

Kosair Charities Pediatric Clinical Research Unit - University of Louisville

🇺🇸

Louisville, Kentucky, United States

Children's Hospital and Medical Center

🇺🇸

Omaha, Nebraska, United States

Children's Hospital-San Diego

🇺🇸

San Diego, California, United States

Miami Children's Hospital

🇺🇸

Miami, Florida, United States

Administrative Site-Hawaii Pacific Health Research Institute

🇺🇸

Honolulu, Hawaii, United States

Arthritis Associates of South Florida

🇺🇸

Delray Beach, Florida, United States

Delray Research Associates

🇺🇸

Delray Beach, Florida, United States

Kapiolani Medical Center for Women and Children

🇺🇸

Honolulu, Hawaii, United States

Kosair Children's Hospital

🇺🇸

Louisville, Kentucky, United States

University of Louisville

🇺🇸

Louisville, Kentucky, United States

University Pediatric Rheumatology of Kentucky

🇺🇸

Louisville, Kentucky, United States

Milton S. Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Philippine General Hospital

🇵🇭

Manila, Philippines

Institute of Pediatrics, Obstetrics and Gynecology

🇺🇦

Kiev, Ukraine

Clinica Ricardo Palma/Sitio de Investigacion de Reumatologia

🇵🇪

San Isidro, Lima, Peru

Department of Cardioreumatology

🇺🇦

Kharkiv, Ukraine

Clinical Research Unit

🇿🇦

Pretoria, Gauteng Province, South Africa

University of Santo Tomas Hospital

🇵🇭

Manila, Philippines

Smolensk Regional Clinical Hospital

🇷🇺

Smolensk, Russian Federation

First Moscow State Medical University I.M. Sechenov of the Minzdravsocrazvitiya of Russia

🇷🇺

Moscow, Russian Federation

Children's National Medical Center / Division of Rheumatology

🇺🇸

Washington, District of Columbia, United States

Akron Children's Hospital

🇺🇸

Akron, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath